Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + lenalidomide versus rituximab maintenance after rituximab-bendamustine in relapsed/refractory follicular lymphoma
2012-003392-18Phase 3Active
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, lenalidomide and bendamustine in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Jan 2014; status: active.
02
Drugs
rituximablenalidomidebendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-003392-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003392-18.